✦ LIBER ✦

Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide

✍ Scribed by Prince, H M; Schenkel, B; Mileshkin, L

Book ID: 110057089
Publisher: Nature Publishing Group
Year: 2007
Tongue: English
Weight: 83 KB
Volume: 21
Category: Article
ISSN: 0887-6924
DOI: 10.1038/sj.leu.2404573

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Assessing response rates in clinical tri

Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide by H Prince, Brad Schenkel and Linda Mileshkin

✍ Durie, B G M; Rajkumar, S V 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 50 KB

Clinical efficacy of a bortezomib, cyclo

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

✍ Yeo-Kyeoung Kim; Sang-Kyun Sohn; Jae-Hoon Lee; Deok-Hwan Yang; Joon-Ho Moon; Jae 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 175 KB

A phase I safety study of enzastaurin pl

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

✍ Irene M. Ghobrial; Nikhil C. Munshi; Brianna N. Harris; Peipei Shi; Nichole M. P 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

Tanespimycin and bortezomib combination

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

✍ Paul G. Richardson; Asher A. Chanan-Khan; Sagar Lonial; Amrita Y. Krishnan; Mich 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 382 KB

A systematic review of phase-II trials o

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

✍ Axel Glasmacher; Corinna Hahn; Florian Hoffmann; Ralph Naumann; Hartmut Goldschm 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB

Single-institute phase 2 study of thalid

Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: Prognostic factors and unique toxicity profile

✍ Yutaka Hattori; Shin-ichiro Okamoto; Naoki Shimada; Tsunayuki Kakimoto; Kunihiko 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB